AI and precision oncology in clinical cancer genomics : from prevention to targeted cancer therapies-an outcomes based patient care

dc.contributor.authorDlamini, Zodwa
dc.contributor.authorSkepu, Amanda
dc.contributor.authorKim, Namkug
dc.contributor.authorMkhabele, Mahlori
dc.contributor.authorKhanyile, Richard
dc.contributor.authorMolefi, Thulo
dc.contributor.authorMbatha, Sikhumbuzo
dc.contributor.authorSetlai, Botle
dc.contributor.authorMulaudzi, Thanyani Victor
dc.contributor.authorMabongo, Mzubanzi
dc.contributor.authorBida, Nndweleni Meshack
dc.contributor.authorKgoebane-Maseko, Minah
dc.contributor.authorMathabe, Kgomotso
dc.contributor.authorLockhat, Zarina I.
dc.contributor.authorKgokolo, C.M.
dc.contributor.authorChauke-Malinga, Nkhensani
dc.contributor.authorRamagaga, Serwalo
dc.contributor.authorHull, Rodney
dc.contributor.emailzodwa.dlamini@up.ac.zaen_US
dc.date.accessioned2023-08-11T05:52:44Z
dc.date.available2023-08-11T05:52:44Z
dc.date.issued2022
dc.description.abstractPrecision medicine is the personalization of medicine to suit a specific group of people or even an individual patient, based on genetic or molecular profiling. This can be done using genomic, transcriptomic, epigenomic or proteomic information. Personalized medicine holds great promise, especially in cancer therapy and control, where precision oncology would allow medical practitioners to use this information to optimize the treatment of a patient. Personalized oncology for groups of individuals would also allow for the use of population group specific diagnostic or prognostic biomarkers. Additionally, this information can be used to track the progress of the disease or monitor the response of the patient to treatment. This can be used to establish the molecular basis for drug resistance and allow the targeting of the genes or pathways responsible for drug resistance. Personalized medicine requires the use of large data sets, which must be processed and analysed in order to identify the particular molecular patterns that can inform the decisions required for personalized care. However, the analysis of these large data sets is difficult and time consuming. This is further compounded by the increasing size of these datasets due to technologies such as next generation sequencing (NGS). These difficulties can be met through the use of artificial intelligence (AI) and machine learning (ML). These computational tools use specific neural networks, learning methods, decision making tools and algorithms to construct and improve on models for the analysis of different types of large data sets. These tools can also be used to answer specific questions. Artificial intelligence can also be used to predict the effects of genetic changes on protein structure and therefore function. This review will discuss the current state of the application of AI to omics data, specifically genomic data, and how this is applied to the development of personalized or precision medicine on the treatment of cancer.en_US
dc.description.departmentAnatomical Pathologyen_US
dc.description.departmentMaxillo-Facial and Oral Surgeryen_US
dc.description.departmentMedical Oncologyen_US
dc.description.departmentOtorhinolaryngologyen_US
dc.description.departmentRadiologyen_US
dc.description.departmentSurgeryen_US
dc.description.departmentUrologyen_US
dc.description.librarianhj2023en_US
dc.description.sponsorshipThe South African Medical Research Council (SAMRC) and the National Research Foundation (NRF).en_US
dc.description.urihttps://www.elsevier.com/locate/imuen_US
dc.identifier.citationDlamini, Z., Skepu, A., Kim, N. et al. 2022, 'AI and precision oncology in clinical cancer genomics: From prevention to targeted cancer therapies-an outcomes based patient care', Informatics in Medicine Unlocked, vol. 31, art. 100965, pp. 1-12, doi : 10.1016/j.imu.2022.100965.en_US
dc.identifier.issn2352-9148
dc.identifier.other10.1016/j.imu.2022.100965
dc.identifier.urihttp://hdl.handle.net/2263/91867
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.subjectPrecision medicineen_US
dc.subjectPrecision oncologyen_US
dc.subjectCancer therapy and controlen_US
dc.subjectPersonalized oncologyen_US
dc.subjectPersonalized medicineen_US
dc.subjectNext-generation sequencing (NGS)en_US
dc.subjectArtificial intelligence (AI)en_US
dc.subjectMachine learningen_US
dc.titleAI and precision oncology in clinical cancer genomics : from prevention to targeted cancer therapies-an outcomes based patient careen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Dlamini_AI_2022.pdf
Size:
5.74 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: